|
Abbvie Inc. (ABBV) DCF -Bewertung
US | Healthcare | Drug Manufacturers - General | NYSE
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
AbbVie Inc. (ABBV) Bundle
Entdecken Sie den wahren Wert von Abbvie Inc. (ABBV) mit unserem erweiterten DCF -Taschenrechner! Passen Sie wesentliche Annahmen an, erkunden Sie verschiedene Szenarien und bewerten Sie, wie sich Änderungen auf die Bewertung der Abbvie Inc. (ABBV) auswirken - alles innerhalb einer bequemen Excel -Vorlage.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45,804.0 | 56,197.0 | 58,054.0 | 54,318.0 | 56,334.0 | 59,611.3 | 63,079.3 | 66,749.1 | 70,632.3 | 74,741.5 |
| Revenue Growth, % | 0 | 22.69 | 3.3 | -6.44 | 3.71 | 5.82 | 5.82 | 5.82 | 5.82 | 5.82 |
| EBITDA | 21,148.0 | 28,280.0 | 31,424.0 | 17,308.0 | 14,910.0 | 24,912.0 | 26,361.3 | 27,895.0 | 29,517.8 | 31,235.0 |
| EBITDA, % | 46.17 | 50.32 | 54.13 | 31.86 | 26.47 | 41.79 | 41.79 | 41.79 | 41.79 | 41.79 |
| Depreciation | 6,471.0 | 8,521.0 | 8,467.0 | 8,698.0 | 8,386.0 | 8,914.8 | 9,433.4 | 9,982.2 | 10,563.0 | 11,177.5 |
| Depreciation, % | 14.13 | 15.16 | 14.58 | 16.01 | 14.89 | 14.95 | 14.95 | 14.95 | 14.95 | 14.95 |
| EBIT | 14,677.0 | 19,759.0 | 22,957.0 | 8,610.0 | 6,524.0 | 15,997.2 | 16,927.9 | 17,912.7 | 18,954.8 | 20,057.6 |
| EBIT, % | 32.04 | 35.16 | 39.54 | 15.85 | 11.58 | 26.84 | 26.84 | 26.84 | 26.84 | 26.84 |
| Total Cash | 8,479.0 | 9,830.0 | 9,229.0 | 12,816.0 | 5,555.0 | 10,176.4 | 10,768.4 | 11,394.9 | 12,057.8 | 12,759.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 8,822.0 | 9,977.0 | 11,254.0 | 11,155.0 | 10,919.0 | 11,483.3 | 12,151.4 | 12,858.3 | 13,606.4 | 14,398.0 |
| Account Receivables, % | 19.26 | 17.75 | 19.39 | 20.54 | 19.38 | 19.26 | 19.26 | 19.26 | 19.26 | 19.26 |
| Inventories | 3,310.0 | 3,128.0 | 3,579.0 | 4,099.0 | 4,181.0 | 4,044.7 | 4,280.0 | 4,529.0 | 4,792.5 | 5,071.3 |
| Inventories, % | 7.23 | 5.57 | 6.16 | 7.55 | 7.42 | 6.79 | 6.79 | 6.79 | 6.79 | 6.79 |
| Accounts Payable | 2,276.0 | 2,882.0 | 2,934.0 | 3,688.0 | 2,945.0 | 3,239.1 | 3,427.6 | 3,627.0 | 3,838.0 | 4,061.3 |
| Accounts Payable, % | 4.97 | 5.13 | 5.05 | 6.79 | 5.23 | 5.43 | 5.43 | 5.43 | 5.43 | 5.43 |
| Capital Expenditure | -798.0 | -787.0 | -695.0 | -777.0 | .0 | -687.9 | -728.0 | -770.3 | -815.1 | -862.6 |
| Capital Expenditure, % | -1.74 | -1.4 | -1.2 | -1.43 | 0 | -1.15 | -1.15 | -1.15 | -1.15 | -1.15 |
| Tax Rate, % | -15.12 | -15.12 | -15.12 | -15.12 | -15.12 | -15.12 | -15.12 | -15.12 | -15.12 | -15.12 |
| EBITAT | 19,937.9 | 17,557.8 | 20,161.7 | 6,699.3 | 7,510.7 | 14,541.2 | 15,387.2 | 16,282.4 | 17,229.6 | 18,232.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 15,754.9 | 24,924.8 | 26,257.7 | 14,953.3 | 15,307.7 | 22,634.2 | 23,377.7 | 24,737.8 | 26,176.9 | 27,699.8 |
| WACC, % | 6.3 | 6.22 | 6.22 | 6.15 | 6.3 | 6.24 | 6.24 | 6.24 | 6.24 | 6.24 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 103,670.3 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 28,669 | |||||||||
| Terminal Value | 1,047,581 | |||||||||
| Present Terminal Value | 774,131 | |||||||||
| Enterprise Value | 877,801 | |||||||||
| Net Debt | 61,620 | |||||||||
| Equity Value | 816,181 | |||||||||
| Diluted Shares Outstanding, MM | 1,773 | |||||||||
| Equity Value Per Share | 460.34 |
What You Will Receive
- Real AbbVie Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Complete Customization: Modify all essential parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to evaluate the impact of changes on AbbVie's fair value.
- Flexible Excel Template: Designed for quick edits, scenario analysis, and comprehensive projections.
- Time-Efficient and Precise: Avoid building models from the ground up while ensuring accuracy and adaptability.
Key Features
- Real-Life ABBV Data: Pre-filled with AbbVie’s historical financials and forward-looking projections.
- Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
- User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.
How It Works
- Step 1: Download the prebuilt Excel template with AbbVie Inc.'s (ABBV) data included.
- Step 2: Explore the pre-filled sheets and familiarize yourself with the key metrics.
- Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view recalculated results, including AbbVie Inc.'s (ABBV) intrinsic value.
- Step 5: Make informed investment decisions or generate reports using the outputs.
Why Choose This Calculator for AbbVie Inc. (ABBV)?
- Comprehensive Tool: Features DCF, WACC, and financial ratio analyses tailored for AbbVie Inc. (ABBV).
- Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios.
- Detailed Insights: Automatically calculates AbbVie Inc. (ABBV)’s intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on AbbVie Inc. (ABBV).
Who Should Use This Product?
- Investors: Accurately assess AbbVie's fair value prior to making investment choices.
- CFOs: Utilize a professional-grade DCF model for precise financial reporting and analysis.
- Consultants: Efficiently modify the template for client valuation reports.
- Entrepreneurs: Discover insights into financial modeling practices employed by leading pharmaceutical companies.
- Educators: Implement it as a teaching resource to illustrate valuation techniques.
What the Template Contains
- Preloaded ABBV Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.